A daily compilation of articles, manuscripts, and news focused on the ADC market and compiled for the scientists who are making the cure everyday.
Friday, May 17, 2019
The strange path of Mylotarg
Pharmacokinetic/ Pharmacodynamic Modeling To Support The Re‐Approval Of Gemtuzumab Ozogamicin
This is a really cool use of in silico testing to facilitate the package for regulatory approval. They have used the data set that existed, and then plugged it into existing models and were able to tease out the fact that there was a real therapeutic benefit at the correct dose.
Clearly this is not sufficient in itself to reapprove Mylotarg, but it was part of the package. Pretty interesting stuff.
Subscribe to: Post Comments (Atom)
Post a Comment